News and Events

Deep-imaging study reveals extensive variability in 3D configuration of genomes between cells

A new study analyzing chromatin in single cells using advanced imaging methods, led by CCR Director Tom Misteli, Ph.D., has revealed more heterogeneity in the 3D configuration of genomes than previously thought.

New strategy for treating brain tumors with mutations in metabolic enzymes

Cancers with mutations in key metabolic enzymes disrupt oxygen metabolism and cause a buildup of reactive oxygen species in mice. This mutation is found in about 80 percent of grade II/III gliomas, or brain tumors, in humans. By inhibiting the action of a protein that allows cancer cells to survive, investigators have potentially found a new strategy for treating cancers with these mutations.

Recap: Grand Rounds with Felicia Knaul, Ph.D.

Nearly 200 CCR staff attended a special Grand Rounds lecture this month featuring Felicia Knaul, Ph.D., an expert in palliative care. Dr. Knaul, a professor at the Leonard M. Miller School of Medicine and Director of the University of Miami Institute for Advanced Study of the Americas, discussed the unequal access to pain and palliative care around the world, particularly related to morphine for pain relief, and the critical importance of educating providers.The lecture, held February 1, was sponsored by CCR’s Women Scientist Advisors (WSAs).

A scanning electron micrograph of a T lymphocyte

Researchers identify a key molecule that enhances T cell-based immunotherapy

The transcription factor c-Myb plays a critical role in regulating T cell stemness. Researchers showed that increasing expression of this transcription factor in T cells launches a powerful, long-lasting antitumor response in mice.

Steve Rosenberg receives Szent-Györgi Prize for Progress in Cancer Research

Steve Rosenberg, M.D., Ph.D., Chief of the Surgery Branch, has received the 2019 Szent-Györgi Prize for Progress in Cancer Research. The award recognizes indivuduals with a seminal discovery or a body of work that has resulted in or led toward notable contributions to cancer prevention, diagnosis or treatment, and the discovery has had a lasting impact on the cancer field with a high direct impact of saving lives.

Drug successfully treats WHIM syndrome

Researchers have discovered which genus of human papillomavirus (HPV) is responsible for warts found in patients with WHIM syndrome, a rare autoimmune disease, and determined the drug plerixafor could successfully treat those patients.

Gene mutations in Burkitt lymphoma hint at more effective treatment

Some cases of Burkitt lymphoma have long been thought to be caused by the Epstein-Barr virus. New research is revealing potential genetic mechanisms for how the virus could contribute to the disease.

CCR staff receive NCI-NIA and Curie-NCI awards

Congratulations to the CCR staff who have been awarded the NCI-NIA Joint Fellowship and the funding opportunity offered through the NCI-NIH and PIC3i Curie.

New map of protein interactions hints at the underlying mechanisms of hereditary kidney cancer

A hereditary form of kidney cancer is characterized by high levels of the metabolite fumarate but how the compound fuels cancer remains a mystery. CCR researchers have mapped the proteins that fumarate interacts with, revealing new links between metabolism and malignancy.

New insights into mechanisms key to maintaining KRAS-mutant cancer cell survival

CCR researchers tested nearly 500 different combinations of multi-gene targeting strategies to study the mechanisms that favor the survival of KRAS-mutant colorectal and pancreatic cancer cells over normal cells. This study reveals the previously underappreciated complexity of the signaling network of the KRAS oncogene. Although work remains to be done, the research does suggest potential target combinations for more effective therapeutic interventions.

Breadcrumb